Pioneering a path forward

Group-1505@2x

We’re dedicated to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause.

Group 1958

Learn about our translational research based on the largest known DNA database focused on obesity.

Group 1958

Learn about our clinical development programs with trials in patients with rare obesities linked to variants in certain genes with strong or very strong relevance to the MC4R pathway.

Our news

2024-04-01T08:00:00

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

2024-03-25T08:00:00

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

2024-03-11T16:01:00

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Dedicated to transforming the care of people living with rare genetic diseases of obesity

OUR COMMUNITY

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic diseases of obesity, including:

Proopiomelanocortin
(POMC) Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
Syndrome (BBS)
Alström
Syndrome
POMC or LEPR
Heterozygous Deficiency Obesity
Smith-Magenis
Syndrome
SRC1 Deficiency
Obesity
MC4R Deficiency
Obesity
SH2B1 Deficiency
Obesity
Our Science

Our news

More News